Literature DB >> 8358559

The antiarrhythmic effects of the nucleoside transporter inhibitor, R75231, in anaesthetized pigs.

C L Wainwright1, J R Parratt, H Van Belle.   

Abstract

1. The effect of R75231, an inhibitor of purine nucleoside transport, were examined on ischaemic arrhythmias in anaesthetized pigs. 2. In closed chest pigs (n = 4), R75231 exerted a moderate dose-dependent decrease in mean arterial blood pressure (from 97 +/- 4 mmHg to 95 +/- 4, 90 +/- 1 and 83 +/- 2 mmHg at 25, 50 and 100 micrograms kg-1 respectively) and produced a dose-related shift to the left of the blood pressure dose-response curve to intravenous bolus doses of adenosine. The degree of inhibition of adenosine uptake by R75231, assessed ex vivo in erythrocyte suspensions, was 43 +/- 5%, 64 +/- 13 and 114 +/- 15% at doses of 25, 50 and 100 micrograms kg-1 respectively. 3. In open chest pigs, intravenous injection of R75231 (50 micrograms kg-1; n = 6 and 100 micrograms kg-1; n = 10) induced a dose-related decrease in both systolic and diastolic arterial blood pressure which was more marked than in closed-chest pigs (mean pressure 86 +/- 4 to 70 +/- 2 mmHg and 88 +/- 6 to 60 +/- 6 mmHg with 50 and 100 micrograms kg-1 respectively), without affecting heart rate or myocardial contractility. Coronary artery occlusion in these pigs caused a secondary decrease in blood pressure. This was not observed in controls (n = 10). The lower dose of R75231 did not exert any antifibrillatory effects, whereas the higher dose significantly reduced the incidence of ventricular fibrillation, from 80% in control pigs to 30%. Neither dose modified the incidence of ventricular tachycardia (33% and 40% with 50 and 100 microg kg-1 respectively, compared to 30% in controls) or had any effect on the total number of ventricular ectopic beats (85 +/- 47 and 130 +/- 31 vs 110 +/- 19 in controls). R75231, at a dose of 100 microg kg-1, also attenuated the ischaemia-induced shortening of QRS-interval, but neither dose modified the ST-segment depression seen following occlusion.4. These results show that the nucleoside transport inhibitor, R75231, exerts an antifibrillatory effect ina model of severe myocardial ischaemia in a dose which completely inhibits adenosine uptake ex vivo.However, while this agent has minimal haemodynamic effects in closed chest animals, the reduction in blood pressure induced by R75231 in open-chest pigs cannot be excluded as a possible contributory mechanism of the antiarrhythmic effects of this drug.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8358559      PMCID: PMC2175672          DOI: 10.1111/j.1476-5381.1993.tb13612.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  41 in total

1.  Single-run high-performance liquid chromatography of nucleotides, nucleosides, and major purine bases and its application to different tissue extracts.

Authors:  J Wynants; H Van Belle
Journal:  Anal Biochem       Date:  1985-01       Impact factor: 3.365

2.  Evidence for an A1-adenosine receptor in the guinea-pig atrium.

Authors:  M G Collis
Journal:  Br J Pharmacol       Date:  1983-01       Impact factor: 8.739

3.  Acute management of paroxysmal supraventricular tachycardia: verapamil, adenosine triphosphate or adenosine?

Authors:  B Belhassen; A Pelleg
Journal:  Am J Cardiol       Date:  1984-07-01       Impact factor: 2.778

4.  Antiarrhythmic actions of adenosine in the early stages of experimental myocardial ischaemia.

Authors:  O Fagbemi; J R Parratt
Journal:  Eur J Pharmacol       Date:  1984-04-20       Impact factor: 4.432

5.  Cardioprotective effects of lidoflazine during 1-hour normothermic global ischemia.

Authors:  W Flameng; W Daenen; M Borgers; F Thone; R Xhonneux; A van de Water; H van Belle
Journal:  Circulation       Date:  1981-10       Impact factor: 29.690

6.  Lidoflazine in the early stages of acute myocardial ischaemia.

Authors:  S J Coker; O Fagbemi; J R Parratt
Journal:  Br J Pharmacol       Date:  1982-06       Impact factor: 8.739

7.  Metabolic and functional effects of the nucleoside transport inhibitor R75231 in the ischaemic and blood reperfused rabbit heart.

Authors:  M Galiñanes; Y Qiu; H Van Belle; D J Hearse
Journal:  Cardiovasc Res       Date:  1993-01       Impact factor: 10.787

8.  Dipyridamole: a potent stimulator of prostacyclin (PGI2) biosynthesis.

Authors:  K E Blass; H U Block; W Förster; K Pönicke
Journal:  Br J Pharmacol       Date:  1980-01       Impact factor: 8.739

9.  Prostacyclin--antiarrhythmic or arrhythmogenic? Comparison of the effects of intravenous and intracoronary prostacyclin and ZK36374 during coronary artery occlusion and reperfusion in anaesthetised greyhounds.

Authors:  S J Coker; J R Parratt
Journal:  J Cardiovasc Pharmacol       Date:  1983 Jul-Aug       Impact factor: 3.105

10.  Salvage of ischemic myocardium by dipyridamole in the conscious dog.

Authors:  D S Blumenthal; G M Hutchins; B I Jugdutt; L C Becker
Journal:  Circulation       Date:  1981-11       Impact factor: 29.690

View more
  5 in total

1.  Studies of the nucleoside transporter inhibitor, draflazine, in the human myocardium.

Authors:  M Böhm; C Weinhold; R H Schwinger; J Müller-Ehmsen; D Böhm; H Reichenspurner; B Reichart; E Erdmann
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

Review 2.  Purine metabolism in the heart. Strategies for protection against myocardial ischaemia.

Authors:  K Ver Donck
Journal:  Pharm World Sci       Date:  1994-04-15

3.  Antiarrhythmic effects of BN-063, a newly synthesized adenosine A1 agonist, on myocardial ischaemia in rats.

Authors:  Y M Lee; J W Chern; M H Yen
Journal:  Br J Pharmacol       Date:  1994-08       Impact factor: 8.739

4.  Hemodynamic and neurohumoral effects of various grades of selective adenosine transport inhibition in humans. Implications for its future role in cardioprotection.

Authors:  G A Rongen; P Smits; K Ver Donck; J J Willemsen; R A De Abreu; H Van Belle; T Thien
Journal:  J Clin Invest       Date:  1995-02       Impact factor: 14.808

5.  Adenosine concentration in great cardiac vein is increased in non-ventricular fibrillation dogs.

Authors:  Kazuaki Uchino; Toshiaki Ebina; Tohyoh Nihei; Tomoaki Ishigami; Toshiyuki Ishikawa; Kazuo Kimura; Satoshi Umemura
Journal:  Heart Vessels       Date:  2006-07       Impact factor: 1.814

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.